Profound Medical (TSE:PRN) Posts Earnings Results

Profound Medical (TSE:PRN) posted its quarterly earnings results on Thursday. The company reported C$0.37 earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of C$8.20 million for the quarter. Profound Medical had a negative net margin of 287.94% and a negative return on equity of 86.83%.

Profound Medical Trading Down 1.4%

Shares of TSE:PRN traded down C$0.14 during midday trading on Thursday, reaching C$10.00. The company’s stock had a trading volume of 7,371 shares, compared to its average volume of 15,807. The firm has a 50 day moving average price of C$10.18 and a two-hundred day moving average price of C$8.72. Profound Medical has a fifty-two week low of C$5.23 and a fifty-two week high of C$12.40. The firm has a market capitalization of C$362.93 million, a price-to-earnings ratio of -7.58 and a beta of 0.98. The company has a debt-to-equity ratio of 14.80, a quick ratio of 14.98 and a current ratio of 4.18.

Insider Buying and Selling at Profound Medical

In other news, insider Thomas Michael Tamberrino bought 13,908 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were bought at an average cost of C$9.91 per share, for a total transaction of C$137,828.28. Following the acquisition, the insider directly owned 39,241 shares in the company, valued at approximately C$388,878.31. This trade represents a 54.90% increase in their ownership of the stock. Corporate insiders own 8.62% of the company’s stock.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.